Aichi Medical University, Nippon Zoki Pharmaceutical Co., Ltd., and FRONTEO Healthcare, Inc. Begin Joint Research on Creating...
08 Mayo 2017 - 8:00AM
Treatment of pain will be guided by the KIBIT
artificial intelligence engine.Judgment criteria of a
multidisciplinary chronic pain management team will be utilized to
develop algorithms for the diagnosis and management of chronic
pain.
Aichi Medical University, Nippon Zoki Pharmaceutical Co., Ltd., and
FRONTEO Healthcare, Inc. (“FRONTEO Healthcare”), a subsidiary of
FRONTEO, Inc. (NASDAQ:FTEO) (TSE:2158) that provides medical data
analysis solutions using the artificial intelligence (“AI”) engine
“KIBIT”, announced today that the three parties have begun their
joint research to develop an AI system that supports the diagnosis
and management of chronic pain.
Chronic pain arises from a spectrum of both
known and unknown etiologies. In addition to the tremendous
morbidity which results, it is also a major driver of the increase
in healthcare costs. Optimal diagnosis and treatment of chronic
pain requires a multidisciplinary approach encompassing medical,
neurological, psychosocial, and occupational expertise. As
Japan is an aging society with high stress levels, the number of
patients with chronic pain is expected to increase dramatically
over the next few decades.
Aichi Medical University established Japan’s
first multidisciplinary management and research facility for
chronic pain, the Multidisciplinary Pain Center (the “Pain
Center”). The Pain Center includes anesthesiologists, orthopedic
surgeons, psychiatrists, nurses, physiotherapists, and clinical
psychologists, all highly focused on the management of pain. In
addition, approximately 7,000 patients are cared for annually at
the Pain Center.
The KIBIT joint research will develop algorithms
focused on the diagnosis and treatment of chronic pain. Aichi
Medical University will provide anonymous medical records of
patients with pain and their corresponding multidisciplinary
management. FRONTEO Healthcare will be responsible for the analysis
and optimization of algorithms incorporating this knowledge base
into KIBIT. Nippon Zoki will provide financial support and business
development expertise. After a one-year initiation phase, the
involved parties will proceed with the development of a
commercialized diagnostic platform to support pain management in
Japanese clinics and hospitals. Ultimately, this project will
enable better and more cost effective care of pain management
across Japan.
About Aichi Medical
UniversityAichi Medical University opened in 1972 as a
single-subject university having only a medical department, with
the primary founding principle of “training physicians that can
respond to the needs of a new age, and providing medical service to
the local community.” In the year 2000, with the opening of the
Department of Nursing in order to “train nursing staff with a broad
perspective and high level of education, to respond rapidly and
proactively to a variety of social needs,” it became a medical
university with two departments. The ethos and objective of the
university is “to train personnel to work in medicine and
healthcare in a new era, within a fully-equipped education and
research environment, and to contribute to social welfare,
particularly regional healthcare, and cooperate to international
progress and improvements in healthcare, reflecting the
characteristics of a private university.” Aichi Medical University
will continue to develop these activities even further in the
future, with the fundamental policy of being “a winning medical
university that is highly regarded in society,” and work on new
reforms to reach greater heights in all areas, whether in
education, research or treatment, to win out in the modern
competitive age.URL: http://www.aichi-med-u.ac.jp/
About Nippon Zoki Pharmaceutical Co.,
Ltd.Founded over 75 years ago, with the motto of
“Creativity and Safety,” Nippon Zoki Pharmaceutical Co., Ltd. is a
research-and-development-based pharmaceutical manufacturer involved
in the development, manufacture and sale of prescription
pharmaceuticals and drugstore pharmaceuticals rooted in the needs
of patients and physicians, mainly in the fields of pain treatment,
skin disease, and allergic disease. Its drug Neurotropin is
recommended by the Japan Society of Pain Clinicians as the
first-line treatment for post-herpetic neuralgia, and boasts
top-class figures among analgesics for domestic prescriptions and
sales. In addition to the Japanese market, in 1994 Nippon Zoki
expanded its business to China, and is developing its business
manufacturing and selling its own products in the ASEAN market,
centered on the business in Vietnam it started in 2008. In the
future, it aims to move into the health-tech business, including
management of patient healthcare, support for treatment by
healthcare professionals, and the development of software
healthcare devices to reduce workloads, to contribute further to
clinical practice.URL: http://www.nippon-zoki.co.jp/.
Name: |
Nippon Zoki
Pharmaceutical Co., Ltd. |
Established: |
October 9, 1940 |
Capital: |
100 million yen |
Representative: |
CEO/President Ryusaku
Konishi |
Area of business: |
Manufacture and sale of
prescription pharmaceuticals |
|
Manufacture and sale of
general pharmaceuticals |
|
Production plant
(precision machinery) business |
About FRONTEO, Inc.FRONTEO,
Inc. (“FRONTEO”) (Nasdaq:FTEO) (TSE:2158) supports the analysis of
big data based on behavior informatics by utilizing its technology,
"KIBIT". FRONTEO's KIBIT technology is driven by FRONTEO artificial
intelligence based on knowledge acquired through its litigation
support services. KIBIT incorporates experts' tacit knowledge,
including their experiences and intuitions, and utilizes that
knowledge for big data analysis. FRONTEO continues to expand its
business operations by applying KIBIT to new fields such as
healthcare and marketing. FRONTEO was founded in 2003 as a provider
of e-discovery and international litigation support services. These
services include the preservation, investigation and analysis of
evidence materials contained in electronic data, and computer
forensic investigation. FRONTEO provides e-discovery and litigation
support by making full use of its data analysis platform, "Lit i
View", and its Predictive Coding technology adapted to Asian
languages. The company name was changed from UBIC, Inc. to FRONTEO,
Inc. as of July 1, 2016.
For more information about FRONTEO, contact
global_pr@fronteo.com or visit http://www.fronteo.com/global/.
Safe Harbor StatementThis
announcement contains forward-looking statements. These
forward-looking statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Among other things,
the amount of data that FRONTEO expects to manage this year and the
potential uses for FRONTEO's new service in intellectual
property-related litigation, contain forward-looking statements.
FRONTEO may also make written or oral forward-looking statements in
its reports filed with, or furnished to, the U.S. Securities and
Exchange Commission, in its annual reports to shareholders, in
press releases and other written materials and in oral statements
made by its officers, directors or employees to third parties.
Statements that are not historical facts, including statements
about FRONTEO's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. A number of factors could cause actual results to
differ materially from those contained in any forward-looking
statement, including but not limited to the following: FRONTEO's
goals and strategies; FRONTEO's expansion plans; the expected
growth of the data center services market; expectations regarding
demand for, and market acceptance of, FRONTEO's services; FRONTEO's
expectations regarding keeping and strengthening its relationships
with customers; FRONTEO's plans to invest in research and
development to enhance its solution and service offerings; and
general economic and business conditions in the regions where
FRONTEO provides solutions and services. Further information
regarding these and other risks is included in FRONTEO's reports
filed with, or furnished to the Securities and Exchange Commission.
FRONTEO does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
All information provided in this press release and in the
attachments is as of the date of this press release, and FRONTEO
undertakes no duty to update such information, except as required
under applicable law.
CONTACT:
FRONTEO Global PR
global_pr@fronteo.com
FRONTEO (NASDAQ:FTEO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
FRONTEO (NASDAQ:FTEO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024